These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

237 related articles for article (PubMed ID: 17612904)

  • 21. Metabolic syndrome and cardiovascular risk in primary hypertension.
    Ratto E; Leoncini G; Viazzi F; Vaccaro V; Parodi A; Falqui V; Conti N; Tomolillo C; Deferrari G; Pontremoli R
    J Am Soc Nephrol; 2006 Apr; 17(4 Suppl 2):S120-2. PubMed ID: 16565234
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Aliskiren Trial in Type 2 Diabetes Using Cardio-Renal Endpoints (ALTITUDE): rationale and study design.
    Parving HH; Brenner BM; McMurray JJ; de Zeeuw D; Haffner SM; Solomon SD; Chaturvedi N; Ghadanfar M; Weissbach N; Xiang Z; Armbrecht J; Pfeffer MA
    Nephrol Dial Transplant; 2009 May; 24(5):1663-71. PubMed ID: 19145003
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Oral inhibitors of renin and their potential use as therapeutic agents in treating hypertension].
    Abassi Z; Armaly Z; Nakhoul F; Hoffman A
    Harefuah; 2008 Jun; 147(6):536-42, 573. PubMed ID: 18693632
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Inhibiting the renin-angiotensin system: why and in which patients.
    Berra K; Miller NH
    J Am Acad Nurse Pract; 2009 Jan; 21(1):66-75. PubMed ID: 19125897
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Establishing a new option for target-organ protection: rationale for ARB plus ACE inhibitor combination therapy.
    Cohn JN; Goldman JM
    Am J Hypertens; 2008 Mar; 21(3):248-56. PubMed ID: 18219303
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Risk factors for the development and progression of renal diseases in disadvantaged populations: role of the renin-angiotensin system blockade.
    Maione A; Strippoli GF
    Ethn Dis; 2009; 19(1 Suppl 1):S1-86-9. PubMed ID: 19484883
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Clinical trials in nephrology: success or failure.
    Garcia-Donaire JA; Segura J; Ruilope LM
    Curr Opin Nephrol Hypertens; 2007 Mar; 16(2):59-63. PubMed ID: 17293678
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Glomerular filtration rate and cardiovascular risk: prognostic and therapeutic implications].
    Ratto E; Leoncini G; Viazzi F; Pontremoli R
    G Ital Nefrol; 2008; 25(1):21-31. PubMed ID: 18264915
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Minor abnormalities of renal function: a situation requiring integrated management of cardiovascular risk.
    Segura J; Ruilope LM
    Fundam Clin Pharmacol; 2005 Aug; 19(4):429-37. PubMed ID: 16011729
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Chronic renal disease in renal transplant patients: management of cardiovascular risk factors.
    Fernández-Fresnedo G; Gómez-Alamillo C; Ruiz JC; de Francisco AL; Arias M
    Transplant Proc; 2009 Jun; 41(5):1637-8. PubMed ID: 19545697
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Protecting renal function in the hypertensive patient: clinical guidelines.
    Bakris GL
    Am J Hypertens; 2005 Apr; 18(4 Pt 2):112S-119S. PubMed ID: 15837554
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Angiotensin receptor blockers versus angiotensin-converting enzyme inhibitors: where do we stand now?
    Böhm M
    Am J Cardiol; 2007 Aug; 100(3A):38J-44J. PubMed ID: 17666197
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cardiovascular protection paradigms: is change on the horizon?
    Papademetriou V
    Rev Cardiovasc Med; 2007; 8(4):200-13. PubMed ID: 18192943
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Improving microvascular outcomes in patients with diabetes through management of hypertension.
    McGill JB
    Postgrad Med; 2009 Mar; 121(2):89-101. PubMed ID: 19332966
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Use of angiotensin-converting enzyme inhibitor/angiotensin receptor blocker therapy to reduce cardiovascular events in high-risk patients: part 2.
    Bommer WJ
    Prev Cardiol; 2008; 11(4):215-22. PubMed ID: 19476574
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Arterial hypertension and dyslipidemia in patients with chronic kidney disease (CKD). Anti-platelet aggregation. Goal oriented treatment].
    Cases Amenós A; Goicoechea Diezhandiño M; de Alvaro Moreno F
    Nefrologia; 2008; 28 Suppl 3():39-48. PubMed ID: 19018737
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Adults with diabetes - pharmacological management of hypertension.
    Jackowski L; Crockett J; Rowett D
    Aust Fam Physician; 2008 Jun; 37(6):419-21. PubMed ID: 18523694
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Evidence for the use of urinary albumin as marker of kidney involvement in unselected populations.
    McQueen MJ
    Scand J Clin Lab Invest Suppl; 2008; 241():52-6. PubMed ID: 18569965
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Management of hypertension in peripheral arterial disease: does the choice of drugs matter?
    Singer DR; Kite A
    Eur J Vasc Endovasc Surg; 2008 Jun; 35(6):701-8. PubMed ID: 18375152
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Fewer cases of stroke, atrial fibrillation, diabetes and renal insufficiency. Good treatment of hypertension is more than lowering of blood pressure].
    Baumgart P
    MMW Fortschr Med; 2008 Jan; 150(1-2):52-3. PubMed ID: 18300647
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.